Cancyt

Cancyt

cytarabine

Manufacturer:

Naprod

Distributor:

Multicare
Concise Prescribing Info
Contents
Cytarabine
Indications/Uses
Acute leukemia especially acute non-lymphoblastic leukemia when it is often given in association w/ thioguanine & an anthracycline eg, doxorubicin or daunorubicin. As regimen for Hodgkin's disease, non-Hodgkin's lymphomas, meningeal lymphoma & prophylaxis meningeal leukemia. Blast crisis of chronic myeloid leukemia, & treatment of lymphoma; management of myelodysplasia.
Dosage/Direction for Use
IV Adult & childn Induction of remission in acute leukaemia 100 mg/m2 bid by rapid IV or 100 mg/m2 daily by continuous IV for 5-10 days. Maintenance dose: 75-100 mg/m2 or 1-1.5 mg/kg or more may be given IV, IM or SC once or twice wkly. Refractory disease 3 g/m2 every 12 hr for up to 6 days as IV infusion for at least 1 hr. Leukaemic meningitis 10-30 mg/m2 every 2-4 days intrathecally.
Special Precautions
Monitor blood uric acid because of the risk of hyperuricemia & renal & hepatic function periodically. Impaired liver function.
Adverse Reactions
Bone-marrow depression manifest; nausea & vomiting; hepatic & renal dysfunction, neurotoxicity (particularly via the intrathecal route), rashes, oral & anal ulceration, GI haemorrhage, esophagitis & conjunctivitis; bone & muscle pain syndrome, fever, malaise, conjunctivitis, & rash; local pain, cellulites, & thrombophlebitis at the site of inj; severe GI & CNS effects, including severe ulceration of the GIT, pneumatosis cystoids leading to peritonitis, necrotizing colitis & bowel necrosis, peripheral neuropathy, cerebral & cerebellar dysfunction, w/ personality changes, somnolence, & coma in high dose therapy; corneal toxicity leading to punctuate keratitis & haemorrhagic conjunctivitis, sepsis, liver abscess, severe skin rash leading to desquamation, alopecia & cardiac disorders including pericarditis & fatal cardiomyopathy; pulmonary oedema.
Drug Interactions
May inhibit the action of flucytosine. Possibility of acute pancreatitis on patients previously receiving asparaginase therapy (antineoplastics).
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC01 - cytarabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Cancyt soln for inj 100 mg/mL
Packing/Price
1 mL x 1's;10 mL x 1's;5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in